MedWatch

Bavarian Nordic CEO sees massive sales potential for Covid-19 vaccine after securing state aid

If the company manages to produce a Covid-19 vaccine, the sales potential will be huge, says CEO Paul Chaplin, who is happy about the recent aid agreement reached with the Danish government.

Bavarian Nordic CEO Paul Chaplin | Photo: PR/ Bavarian Nordic

Bavarian Nordic CEO Paul Chaplin predicts huge growth potential for its Covid-19 vaccine, as a EUR 108m financial support agreement with the Danish government fell into place on Monday.

In an interview with Danish financial media Finans, the CEO says that it is hard to put the potential into revenue terms, but that even a small slice of the market is big.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs